Sarah Boyce

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Diego, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Peter Slover, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Sarah Boyce

Form 4 holding Director

OmniAb, Inc.

Security class
Common Stock
Shares / value
68,381
Estimated value
$301,970
Report date
18 Jun 2024
Price
$4.42
Ownership
Direct
Form 4 holding Former Director

LIGAND PHARMACEUTICALS INC

Security class
Common Stock
Shares / value
2,892
Estimated value
$209,121
Report date
01 Nov 2022
Price
$72.31
Ownership
Direct
Form 4 holding Director

Berkeley Lights, Inc.

Security class
Common Stock
Shares / value
1,400
Estimated value
$770
Report date
14 May 2021
Price
$0.5500
Ownership
Direct
Form 4 holding Director

OmniAb, Inc.

Security class
Stock Option (right to buy)
Shares / value
40,000
Estimated value
Report date
18 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Atrium Therapeutics, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
20,000
Estimated value
Report date
27 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

OmniAb, Inc.

Security class
Restricted Stock Units
Shares / value
20,000
Estimated value
Report date
18 Jun 2024
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Berkeley Lights, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
4,900
Estimated value
Report date
14 May 2021
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director

Avidity Biosciences, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
27 Feb 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Former Director

LIGAND PHARMACEUTICALS INC

Security class
Employee Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
01 Nov 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Sarah Boyce

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .